Norgine
Norgine is a European specialist pharmaceutical and consumer healthcare company that develops and commercialises medicines across multiple therapy areas.
- Acquired, subsidiary of Goldman Sachs Asset Management
- Amsterdam, NL
Norgine is a European specialist pharmaceutical and consumer healthcare company that develops and commercialises medicines across multiple therapy areas.
norgine.comCrawled Oct 15, 2026
Media contact: contact@norgine.com Corporate news items are intended for business/trade media and for analysts/investors.
Norgine employs over 1,400 people and has a direct presence in 16 European countries, Australia and New Zealand. The company says it offers employees opportunities to take on new challenges and develop their skills.
Norgine B.V. announced data showing a correlation between higher cleansing scores and increased polyp detection rates during colonoscopy.
Norgine B.V. presented data at United European Gastroenterology Week comparing PLENVU (NER1006) with standard-of-care bowel preparations for segmental colon cleansing.
Norgine announced data comparing the bowel-cleansing efficacy of PLENVU, a 1-litre PEG preparation, with MOVIPREP, a 2-litre PEG and ascorbate preparation.
Norgine is a pharmaceutical company with a European presence and experience spanning more than a century. It describes its integrated infrastructure and partnership approach as helping it develop and deliver products to patients.
Norgine Pharmaceuticals
The European Commission grants marketing authorisation for XOLREMDI (mavorixafor), the first approved treatment for patients with WHIM syndrome in the European Union. Norgine leads the therapy’s commercialisation across Europe under a licensing agreement with X4 Pharmaceuticals.
Apr 2026pharmaphorumNews article
Norgine invests £23 million in its Hengoed, Wales manufacturing site, bringing its total committed investment there to more than £50 million since 2022. The expansion adds production and warehousing capacity and is supported by the UK Government’s Life Sciences Innovative Manufacturing Fund.
Mar 2026PR NewswireNews article
Norgine enters an exclusive in-licensing agreement with Vir Biotechnology to commercialize the tobevibart-plus-elebsiran combination for chronic hepatitis delta in Europe, Australia, and New Zealand. The deal includes an initial reimbursement payment, potential regulatory and commercial milestone payments, and tiered royalties.
Dec 2025PR NewswireNews article
Norgine agrees to acquire Theravia, a pharmaceutical company specializing in rare disease treatments, from its majority shareholder, Mérieux Equity Partners. The deal adds SIKLOS for sickle cell disease, ORPHACOL for bile acid synthesis disorders, and other rare disease products to Norgine’s portfolio.
Apr 2025PR NewswireNews article